CERC-301 is a selective NR2B specific NMDA receptor antagonist being developed as an adjunctive treatment of major depressive disorder (MDD). We believe CERC-301 will have a rapid onset of effect, be well tolerated and may have fewer side effects than the leading adjunctive treatments currently available, such as atypical antipsychotics, whose treatment efficacy is hindered by side effects such as weight gain and increased risk of diabetes. We expect that an adjunctive therapy with the attributes of CERC-301 will lead to superior outcomes and improved compliance.
CERC-301’s mechanism of action is based on ketamine and is an oral, NR2B specific, NMDA receptor antagonist that will be a “first-in-class” medication with the potential for causing a significant reduction in symptoms in a matter of days, compared to weeks or months with conventional therapies. As a new mechanism of action, CERC-301 holds promise as an adjunctive treatment for millions of severely depressed patients who do not respond to existing therapies or require fast-acting treatment in acute situations.